Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis

@article{Undre2011PharmacokineticsOM,
  title={Pharmacokinetics of micafungin in HIV positive patients with confirmed esophageal candidiasis},
  author={Nas Undre and Paul Stevenson and Ezio Baraldi},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
  year={2011},
  volume={37},
  pages={31-38}
}
Esophageal candidiasis (EC) is a common and serious complication in patients infected with the human immunodeficiency virus (HIV). Micafungin has been shown to have dose-related efficacy and to be well tolerated in patients with HIV and EC. This analysis of data from a randomized, double-blind study examined pharmacokinetic parameters of micafungin (dosed at 50, 100, and 150 mg/day) and its metabolites in a subset of patients with HIV and EC. Micafungin exhibited linear, predictable… CONTINUE READING
4 Citations
26 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 26 references

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

  • N de Wet, A Llanos-Cuentas, +4 authors H Diekmann-Berndt
  • Clin Infect Dis
  • 2004
Highly Influential
4 Excerpts

Simultaneous determination of antifungal drug , micafungin , and its two active metabolites in human plasma using high - performance liquid chromatography with fluorescence detection

  • Y Yamato, H Kaneko, +5 authors A Kagayama
  • Jpn J Chemother
  • 2002
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…